ACTRN12617001625369
Recruiting
未知
Evaluating the feasibility of the Fear-Less Triple P 1/2 day workshop with parents of anxious children engaged with Disability Services.
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Anxiety
- Sponsor
- The University of Queensland
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Preliminary evaluation of Fear-less Triple P for parents of anxiety-disordered childreAnxiety disorders in childrenMental Health - AnxietyACTRN12615000514505Vanessa Cobham60
Completed
Not Applicable
Efficacy of delivering the Fear-less Triple P program at two differing levels of intensity for parents of children with anxiety disordersAnxiety disordersMental Health - AnxietyACTRN12615001284550Vanessa Cobham75
Active, not recruiting
Phase 1
A study of the safety and drug effects of levodopa inhalation powder (CVT-301) compared to Standard of Care Observational Cohort in patients with Parkinson’s diseaseEUCTR2014-003799-22-HUCivitas Therapeutics, Inc.365
Active, not recruiting
Phase 1
A study of the safety and drug effects of levodopa inhalation powder (CVT-301) compared to Standard of Care Observational Cohort in patients with Parkinson’s diseaseEUCTR2014-003799-22-CZCivitas Therapeutics, Inc.408
Active, not recruiting
Phase 1
A study of the safety and drug effects of levodopa inhalation powder (CVT-301) compared to Standard of Care Observational Cohort in patients with Parkinson’s diseaseParkinson's Disease With Motor Response Fluctuations (OFF Phenomena)MedDRA version: 19.0Level: LLTClassification code 10034007Term: Parkinson's disease NOSSystem Organ Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2014-003799-22-DECivitas Therapeutics, Inc.408